These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 22687624

  • 1. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
    Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG.
    Biochem Pharmacol; 2012 Aug 15; 84(4):451-8. PubMed ID: 22687624
    [Abstract] [Full Text] [Related]

  • 2. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
    Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG.
    Neoplasia; 2010 May 15; 12(5):366-75. PubMed ID: 20454508
    [Abstract] [Full Text] [Related]

  • 3. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 15; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 4. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
    Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG.
    Mol Cancer Ther; 2007 Feb 15; 6(2):460-70. PubMed ID: 17267661
    [Abstract] [Full Text] [Related]

  • 5. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
    Lyu MA, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Rosenblum MG.
    Biochem Pharmacol; 2010 Nov 01; 80(9):1335-42. PubMed ID: 20654581
    [Abstract] [Full Text] [Related]

  • 6. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
    Parameswaran R, Yu M, Lyu MA, Lim M, Rosenblum MG, Groffen J, Heisterkamp N.
    Leukemia; 2012 Aug 01; 26(8):1786-96. PubMed ID: 22373785
    [Abstract] [Full Text] [Related]

  • 7. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul 01; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
    Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ.
    Mol Cancer Ther; 2010 Jul 01; 9(7):2026-36. PubMed ID: 20606045
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 12. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
    Sun L, Zhang L, Qian J, Yang J, Yi Q, Dong W, Wang M.
    Leuk Res; 2012 Mar 15; 36(3):363-8. PubMed ID: 22000823
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
    Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ.
    J Immunol; 2003 Jul 01; 171(1):88-95. PubMed ID: 12816986
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L.
    Clin Cancer Res; 2007 Oct 01; 13(19):5942-51. PubMed ID: 17908991
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.